WO2005059170A3 - Method for the determination of fibrinolytic activity in blood - Google Patents

Method for the determination of fibrinolytic activity in blood Download PDF

Info

Publication number
WO2005059170A3
WO2005059170A3 PCT/GB2004/005249 GB2004005249W WO2005059170A3 WO 2005059170 A3 WO2005059170 A3 WO 2005059170A3 GB 2004005249 W GB2004005249 W GB 2004005249W WO 2005059170 A3 WO2005059170 A3 WO 2005059170A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
fibrinolysis
blood
determination
amount
Prior art date
Application number
PCT/GB2004/005249
Other languages
French (fr)
Other versions
WO2005059170A2 (en
Inventor
Viveca Nerme
Karin Wahlander
Petter Bjorquist
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Viveca Nerme
Karin Wahlander
Petter Bjorquist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Viveca Nerme, Karin Wahlander, Petter Bjorquist filed Critical Astrazeneca Ab
Publication of WO2005059170A2 publication Critical patent/WO2005059170A2/en
Publication of WO2005059170A3 publication Critical patent/WO2005059170A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

The present invention relates to an assay method for measuring the effect of an agent on fibrinolysis comprising the steps of: (a) providing a test sample comprising: (i) a fibrinolysis inhibitor and/or a zymogen of a fibrinolysis inhibitor; and (ii) an agent; (b) activating the coagulation system; and (c) measuring the amount of fibrin degradation products that are formed; wherein the difference between (i) the amount of fibrin degradation products formed in the presence of the agent and (ii) the amount of fibrin degradation products formed in the absence of the agent is indicative of the effect of said agent on fibrinolysis.
PCT/GB2004/005249 2003-12-17 2004-12-14 Method for the determination of fibrinolytic activity in blood WO2005059170A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303417-0 2003-12-17
SE0303417A SE0303417D0 (en) 2003-12-17 2003-12-17 Screenshot

Publications (2)

Publication Number Publication Date
WO2005059170A2 WO2005059170A2 (en) 2005-06-30
WO2005059170A3 true WO2005059170A3 (en) 2005-08-11

Family

ID=30439730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/005249 WO2005059170A2 (en) 2003-12-17 2004-12-14 Method for the determination of fibrinolytic activity in blood

Country Status (2)

Country Link
SE (1) SE0303417D0 (en)
WO (1) WO2005059170A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082340A1 (en) * 2007-12-20 2009-07-02 Astrazeneca Ab Method for monitoring the progression of fibrinolysis'646

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378139A2 (en) * 1989-01-10 1990-07-18 Dr. Karl Thomae GmbH Method for the determination of the total fibrinolytic activity in plasma
US6472161B1 (en) * 1992-10-15 2002-10-29 Robert F. Baugh Method of evaluating blood clot lysis condition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378139A2 (en) * 1989-01-10 1990-07-18 Dr. Karl Thomae GmbH Method for the determination of the total fibrinolytic activity in plasma
US6472161B1 (en) * 1992-10-15 2002-10-29 Robert F. Baugh Method of evaluating blood clot lysis condition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMIRAL J ET AL: "Evaluation of the fibrinolytic potential on plasma: Physiological and pathological variations, and associations with cardio-vascular disease risk factors", FIBRINOLYSIS AND PROTEOLYSIS, vol. 13, no. SUPPL. 1, 1999, & LEIDEN FIBRINOLYSIS AND PROTEOLYSIS WORKSHOP 7 ON EXTRACELLULAR PROTEOLYSIS AND EPIDEMIOLOGY; LEIDEN, NETHERLANDS; APRIL 22-24, 1998, pages 1 - 10, XP009047670, ISSN: 1369-0191 *
LEURS JUDITH ET AL: "Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma.", THROMBOSIS AND HAEMOSTASIS, vol. 89, no. 2, February 2003 (2003-02-01), pages 264 - 271, XP009047650, ISSN: 0340-6245 *

Also Published As

Publication number Publication date
WO2005059170A2 (en) 2005-06-30
SE0303417D0 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
Ellis et al. Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study.
Lange et al. Ecarin chromogenic assay–a new method for quantitative determination of direct thrombin inhibitors like hirudin
WO2002066671A3 (en) Improved method for detection of atp
WO2007089777A3 (en) Method and apparatus for assaying blood clotting
IL144839A0 (en) Oligopeptide derivatives for the electrochemical measurement of protease activity
WO2003093788A3 (en) Test strip and method for determining concentration of creatinine in a body fluid
WO2006030232A3 (en) Monitoring of wounds by measurement of protease and protease inhibitor levels in wound fluids
EP1221620A3 (en) Method for performing activated clotting time test with reduced sensitivity to the presence of aprotinin and for assessing aprotinin sensitivity
WO2002034110A3 (en) Method of determining global coagulability and hemostatic potential
US5057414A (en) Method for the determination of the activity of serine proteases or serine protease inhibitors
WO2008081094A3 (en) Method for the functional measurement of plasmatic thromboduline activity
Schousboe et al. Factor XIIa is a kinetically favorable plasminogen activator
US7338777B2 (en) Method for determining the biological activity of defibrotide
JP7393006B2 (en) fibrinogen test
ATE73500T1 (en) ANALYTICAL METHODS AND MEANS FOR DETECTING ESTEROLYTIC AND/OR PROTEOLYTIC ENZYMES.
DE60029413D1 (en) ENZYMATIC MEASUREMENT OF MYCOPHENOLIC ACID
WO2002034109A3 (en) A reagent and kit for determining global coagulability and hemostatic potential
EP0168738B1 (en) Single step protease inhibitor assay
WO2005059170A3 (en) Method for the determination of fibrinolytic activity in blood
de Araújo et al. Coagulant and anticoagulant activities of Bothrops lanceolatus (Fer de lance) venom
WO2002038799A3 (en) Detection of proteases and screening for protease inhibitors
WO2004005888A3 (en) Method for metal analysis and speciation and biosensor for effecting the method
WO2006068469A8 (en) Methods for the functional determination of mannan-binding-lectin associated serine proteases (masps) and complexes thereof
WO2000050904A8 (en) Test kit for analysing factor viii-splitting protease
EP1247870A3 (en) Test system for the determination of proteases, active in-vivo in haemostasis, in biological fluids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase